Equity · Healthcare
CNTA
NGMCentessa Pharmaceuticals (CNTA)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for CNTA to draw a line in its place.
Have Centessa Pharmaceuticals (CNTA) insiders bought or sold shares recently?
CNTA has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 24 June 2026.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 24 Jun 2026 | Medicxi Ventures Management (Jersey) Ltd10% Owner | Sell | 19,963,157 | — |
| 24 Jun 2026 | INDEX VENTURES LIFE VI (JERSEY) L.P.10% Owner | Sell | 9,961,789 | — |
| 26 Mar 2026 | Anderson Karen M.Chief People Officer | Sell | 41,076 | 1.2M USD |
| 26 Mar 2026 | Weinhoff Gregory MChief Business Officer | Sell | 23,998 | 720K USD |
| 17 Mar 2026 | Anderson Karen M.Chief People Officer | Sell | 10,043 | 282K USD |
| 16 Mar 2026 | Anderson Karen M.Chief People Officer | Sell | 64,768 | 1.8M USD |
| 13 Mar 2026 | Anderson Karen M.Chief People Officer | Sell | 120,029 | 3.2M USD |
| 13 Mar 2026 | Weinhoff Gregory MChief Business Officer | Sell | 73,196 | 1.9M USD |
| 02 Feb 2026 | HUSSAIN IQBAL JChief Legal Officer | Sell | 38,951 | 980K USD |
| 30 Jan 2026 | HUSSAIN IQBAL JChief Legal Officer | Sell | 1,010 | 25K USD |
| 09 Dec 2025 | Accardi Mario AlbertoPresident, Orexin Program | Sell | 10,000 | 288K USD |
| 08 Dec 2025 | Accardi Mario AlbertoPresident, Orexin Program | Sell | 10,000 | 300K USD |
| Sold | 17 open-market sales | 30,418,017 | $13.40M |
Showing the 12 most recent of 17 open-market trades in this window. The figures above count all of them.
36 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 24 Jun 2026 | Accardi Mario AlbertoChief Executive Officer | Other | 243,282 | |
| 24 Jun 2026 | Anderson Karen M.Chief People Officer | Other | 62,085 | |
| 24 Jun 2026 | Bush Tia LChief Technology & Quality Ofc | Other | 147,954 | |
| 24 Jun 2026 | Weinhoff Gregory MChief Business Officer | Other | 65,925 | |
| 24 Jun 2026 | GOYAL ARJUNDirector | Other | 462,585 | |
| 24 Jun 2026 | De Rubertis FrancescoDirector | Other | 19,963,157 | |
| 24 Jun 2026 | Kanes StephenChief Medical Officer | Other | 120,000 | |
| 24 Jun 2026 | Deferiere RaphaelChief Accounting Officer | Other | 11,000 | |
| 24 Jun 2026 | Crowley John JChief Financial Officer | Other | 45,000 | |
| 24 Jun 2026 | HUSSAIN IQBAL JChief Legal Officer | Other | 123,145 | |
| 01 May 2026 | Accardi Mario AlbertoChief Executive Officer | Tax withheld | 604 | 24K USD |
| 26 Mar 2026 | Anderson Karen M.Chief People Officer | Option exercise | 41,076 | 329K USD |
Showing the 12 most recent of 36 compensation filings in this window. The figures above count all of them.
Which funds hold Centessa Pharmaceuticals (CNTA)?
0 of the 45 institutional funds we track reported a Centessa Pharmaceuticals position for the quarter ended 30 Jun 2026; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Baker Bros. Advisors | Exited | |||
| Balyasny Asset Management | Exited | |||
| Citadel Advisors | Exited | |||
| D. E. Shaw & Co. | Exited | |||
| Marshall Wace | Exited | |||
| Maverick Capital | Exited | |||
| Millennium Management | Exited | |||
| Point72 Asset Management | Exited | |||
| Renaissance Technologies | Exited | |||
| Two Sigma Investments | Exited |
What has been filed or recorded for Centessa Pharmaceuticals (CNTA)?
The filings we hold for Centessa Pharmaceuticals, newest first: 6 quarterly earnings reports and 2 annual reports, the latest dated 31 Mar 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.52 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.46 USD | Revenue $15M |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.41 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.38 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.20 USD | Revenue $15M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.06 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.37 USD | |
| 30 Jun 2024 | Quarterly earnings | Q2 2024 reported | EPS −0.40 USD |
Centessa Pharmaceuticals (CNTA): frequently asked questions
Have Centessa Pharmaceuticals insiders bought or sold shares recently?
No Centessa Pharmaceuticals insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 24 Jun 2026 (SEC Form 4). See Insiders
Which funds own Centessa Pharmaceuticals?
0 of the 45 funds we track reported a Centessa Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, Balyasny Asset Management and Citadel Advisors. See Funds
When did Centessa Pharmaceuticals last report earnings?
Centessa Pharmaceuticals last reported earnings on 31 Mar 2026 for Q1 2026, with EPS of −0.52 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts
- SEC EDGARreported earnings figures and scheduled report dates